Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Chronic inflammation

Public_Health

Public Health Today—March 27, 2026

This weekly update in Public Health highlights new population-level research,…

Public_Health

Public Health Video Recap—January 30, 2026

This biweekly Public Health video recap summarizes the latest developments…

Endocrinology

Endocrinology Today—December 16, 2025

Catch up on this week’s endocrinology highlights—from major developments and…

Immunology

Immunology Today—December 10, 2025

This week’s Immunology update highlights key advances in gene therapy,…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
LucidWargames
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Axoft $55 million Series A
Lucid Diligence Brief: Greywolf Therapeutics and Genomics strategic partnership
Public Health Today—May 1, 2026
Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration for cancer trispecific HH160
Vaccines Today—April 30, 2026

Tags

Advanced Solid Tumors Asciminib ASP2957 Ayushman Bharat Digital Health Mission Baylor College Of Medicine CEREGLIDE 57 Chronic disease mortality conduction-system pacing cost reduction DIPS Arena Enzalutamide FDA Digital Health Advisory FG001 GLP-1 Receptor Agonists Glucagon-Like Peptide-1 Receptor Agonists gout flares hospital adoption Human Immunodeficiency Virus Pre-Exposure Prophylaxis Indo-French Centre for AI in Health Inimmune Jaypirca live biotherapeutic product Metastatic Cervical Cancer MicroRNAs Mucopolysaccharidosis Type II Multiple System Atrophy naxtarubicin OCALIVA patient enrollment PPMS RETFound Plus Rhythm Pharmaceuticals Rinvoq Rituximab Sec61 Spikevax SPR Stanford Medicine Subvalvular Spacer Sutra Medical TG Therapeutics Transgene Ver-A-T1D Verve Medical Wolters Kluwer

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Axoft $55 million Series A
Lucid Diligence Brief: Greywolf Therapeutics and Genomics strategic partnership
Public Health Today—May 1, 2026
Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration for cancer trispecific HH160
Vaccines Today—April 30, 2026

TAGS

Advanced Solid Tumors Asciminib ASP2957 Ayushman Bharat Digital Health Mission Baylor College Of Medicine CEREGLIDE 57 Chronic disease mortality conduction-system pacing cost reduction DIPS Arena Enzalutamide FDA Digital Health Advisory FG001 GLP-1 Receptor Agonists Glucagon-Like Peptide-1 Receptor Agonists gout flares hospital adoption Human Immunodeficiency Virus Pre-Exposure Prophylaxis Indo-French Centre for AI in Health Inimmune Jaypirca live biotherapeutic product Metastatic Cervical Cancer MicroRNAs Mucopolysaccharidosis Type II Multiple System Atrophy naxtarubicin OCALIVA patient enrollment PPMS RETFound Plus Rhythm Pharmaceuticals Rinvoq Rituximab Sec61 Spikevax SPR Stanford Medicine Subvalvular Spacer Sutra Medical TG Therapeutics Transgene Ver-A-T1D Verve Medical Wolters Kluwer

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy